Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label

Executive Summary

With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.

You may also be interested in...



Otsuka, Lundbeck Seek Alzheimer's Agitation Claim For Antipsychotic

Otsuka and Lundbeck are seeking to expand the use of psychiatry drug Rexulti into Alzheimer's agitation to up the product's commercial prospects, but mixed Phase III data for the drug mean a third regulatory nod is uncertain.

Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification

The private company may be behind the leaders, but with a long-term plan and a strategy of coming in with complementary therapies like the 5-HT6 receptor antagonist idalopirdine and the dopamine antagonist Rexulti (brexpiprazole), it could be a stable player in Alzheimer's.

FDA approves Otsuka/Lundbeck atypical antipsychotic Rexulti

The FDA late on 10 July approved Otsuka's and Lundbeck's new drug application (NDA) to market Rexulti (brexpiprazole), an atypical antipsychotic, as adjunctive treatment for adults with major depressive disorder (MDD), which affects about 15 million adults in the US, and as a treatment for adults with schizophrenia, which affects about 2.4 million American adults.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel